市場調査レポート

商品コード

1647465

前立腺肥大症治療市場規模、シェア、成長分析：治療法別、タイプ別、製品別、エンドユーザー別、地域別 - 産業予測 2025年～2032年

Benign Prostatic Hyperplasia Treatment Market Size, Share, and Growth Analysis, By Treatment (Minimal Invasive Surgery, Invasive Surgery), By Type (Drug Treatment, Surgical Treatment), By Product, By End User, By Region - Industry Forecast 2025-2032

出版日: 2025年01月29日
発行: SkyQuest
ページ情報: 英文 157 Pages
納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 760,921円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 890,134円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,019,347円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=143.57円

全表示
概要
目次

概要

サンプル依頼リストに入れる

前立腺肥大症治療の世界市場規模は、2023年に114億5,000万米ドルと評価され、2024年の120億8,000万米ドルから2032年には185億4,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは5.5％で成長する見通しです。

前立腺肥大症（BPH）治療市場は、いくつかの重要な要因によって大きな成長を遂げています。高齢化によってBPHの世界の有病率が上昇し、治療を求める患者層が拡大しています。その結果、経尿道的前立腺切除術（TURP）、レーザー治療、前立腺動脈塞栓術（PAE）のような革新的で低侵襲な手技に対する需要が増加しており、これらの手技は回復時間の短縮や合併症の減少といった利点をもたらしています。さらに、公衆衛生への取り組みや教育を通じて前立腺肥大症に対する認識が高まったことで、症状の認知度が向上し、早期の診断と治療につながっています。さらに、支持的な規制の枠組みや有利な償還政策が先進的な治療オプションの採用を後押ししており、この分野の市場拡大をさらに後押ししています。

市場概要
薬物治療
- アルファ遮断薬
- アルフゾシン
- ドキサゾシン
- タムスロシン
- シロドシン
- その他のアルファ遮断薬
- 5-α-リダクターゼ阻害剤
- フィナステリド
- デュタステリド
- その他の薬物クラス
外科的治療
- 経尿道的前立腺切除術（TURP）
- 経尿道マイクロ波温熱療法（TUMT）
- 経尿道的前立腺針焼灼術（TUNA）
- レーザー治療
- 前立腺ステント
- ウロリフトセラピー
- レザムセラピー
- その他の手術

前立腺肥大症治療市場規模：製品別& CAGR（2025-2032）

市場概要
切除鏡
泌尿器科レーザー
高周波アブレーション
電極
カテーテル
前立腺ステント
インプラント
その他

前立腺肥大症治療市場規模：エンドユーザー別& CAGR（2025-2032）

市場概要
在宅ヘルスケア
病院・クリニック
調査と製造

前立腺肥大症治療市場規模：地域別& CAGR（2025-2032）

北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他欧州地域
アジア太平洋地域
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋地域
ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
中東・アフリカ
- GCC諸国
- 南アフリカ
- その他中東・アフリカ

競合情報

上位5社の比較
主要企業の市場ポジショニング（2024年）
主な市場企業が採用した戦略
市場の最近の動向
企業の市場シェア分析（2024年）
主要企業の企業プロファイル
- 会社概要
- 製品ポートフォリオ分析
- セグメント別シェア分析
- 収益の前年比比較（2022-2024）

主要企業プロファイル

Boston Scientific Corporation（USA）
Pfizer Inc.（USA）
GlaxoSmithKline plc（UK）
Eli Lilly and Company（USA）
Abbott Laboratories（USA）
Astellas Pharma Inc.（Japan）
Sanofi S.A.（France）
Merck & Co., Inc.（USA）
Teleflex Incorporated（USA）
Olympus Corporation（Japan）
Coloplast Group（Denmark）
Asahi Kasei Corporation（Japan）
Allergan plc（Ireland）
IPG Photonics Corporation（USA）
Richard Wolf GmbH（Germany）
Biolitec AG（Austria）
Urologix, LLC（USA）
Procept BioRobotics Corporation（USA）
Lumenis Ltd.（Israel）
KARL STORZ SE & Co. KG（Germany）

結論と推奨事項

Product Code: SQMIG35E2045

Global Benign Prostatic Hyperplasia Treatment Market size was valued at USD 11.45 billion in 2023 and is poised to grow from USD 12.08 billion in 2024 to USD 18.54 billion by 2032, growing at a CAGR of 5.5% during the forecast period (2025-2032).

The market for Benign Prostatic Hyperplasia (BPH) treatment is experiencing significant growth due to several key factors. The rising global prevalence of BPH, driven by an aging population, is expanding the patient base seeking treatment. Consequently, there is increased demand for innovative, minimally invasive procedures like transurethral resection of the prostate (TURP), laser therapy, and prostatic artery embolization (PAE), which offer benefits such as shorter recovery times and fewer complications. Furthermore, heightened awareness of BPH through public health initiatives and education has improved symptom recognition, leading to earlier diagnoses and treatment. Moreover, supportive regulatory frameworks and favorable reimbursement policies are encouraging the adoption of advanced treatment options, further propelling market expansion in this sector.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Benign Prostatic Hyperplasia Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Benign Prostatic Hyperplasia Treatment Market Segments Analysis

Global Benign Prostatic Hyperplasia Treatment Market is segmented by Treatment, Type, Product, End User and region. Based on Treatment, the market is segmented into Minimal Invasive Surgery and Invasive Surgery. Based on Type, the market is segmented into Drug Treatment and Surgical Treatment. Based on Product, the market is segmented into Resectoscopes, Urology Laser, Radiofrequency Ablation, Electrodes, Catheters, Prostatic Stents, Implants and Others. Based on End User, the market is segmented into Home Healthcare, Hospitals & Clinics and Research & Manufacturing. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Benign Prostatic Hyperplasia Treatment Market

The increasing awareness of benign prostatic hyperplasia (BPH) and its related symptoms is paving the way for earlier detection and diagnosis. Various stakeholders-including governments, healthcare organizations, and advocacy groups-are engaged in efforts to raise awareness through campaigns and screening initiatives focused on BPH. This proactive approach to early intervention and timely treatment not only helps men seek help sooner but also substantially drives the expansion of the BPH treatment market. As awareness grows and initiatives proliferate, a greater number of patients will be likely to pursue available treatment options, thereby enhancing market growth.

Restraints in the Global Benign Prostatic Hyperplasia Treatment Market

The global Benign Prostatic Hyperplasia (BPH) treatment market faces significant restraints due to the expiration of patents on key medications, which has led to an influx of generic versions of treatments like alpha-blockers and 5-alpha reductase inhibitors. This shift has created pricing pressures that negatively impact the revenue streams of branded products. As generic alternatives become more widely available, they offer patients more affordable treatment options, thereby altering market dynamics. Consequently, this heightened competition could hinder the growth potential of branded therapies, making it essential for companies to adapt to the evolving landscape to maintain their market positions.

Market Trends of the Global Benign Prostatic Hyperplasia Treatment Market

The Global Benign Prostatic Hyperplasia (BPH) treatment market is experiencing a marked shift toward minimally invasive procedures, reflecting a broader trend in urological care that prioritizes patient comfort and recovery. Techniques like transurethral resection of the prostate (TURP), laser ablation, and prostatic urethral lift (PUL) are gaining popularity due to their advantages over traditional surgical methods, including reduced hospital stays, quicker recovery times, and fewer postoperative complications. This movement aligns with the growing emphasis on patient-centered care and enhancing the quality of life, as well as the need to optimize healthcare costs, positioning minimally invasive treatments as a driving force in the BPH market's evolution.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Benign Prostatic Hyperplasia Treatment Market Size by Treatment & CAGR (2025-2032)

Market Overview
Minimal Invasive Surgery
Invasive Surgery

Global Benign Prostatic Hyperplasia Treatment Market Size by Type & CAGR (2025-2032)

Market Overview
Drug Treatment
- Alpha Blockers
- Alfuzosin
- Doxazosin
- Tamsulosin
- Silodosin
- Other Alpha Blockers
- 5-Aplha Reductase Inhibitors
- Finasteride
- Dutasteride
- Other Drug Classes
Surgical Treatment
- Transurethral Resection of the Prostate (TURP)
- Transurethral Microwave Thermotherapy (TUMT)
- Transurethral Needle Ablation of the Prostate (TUNA)
- Laser Therapy
- Prostatic Stenting
- UroLift Therapy
- Rezum Therapy
- Other Surgeries

Global Benign Prostatic Hyperplasia Treatment Market Size by Product & CAGR (2025-2032)

Market Overview
Resectoscopes
Urology Laser
Radiofrequency Ablation
Electrodes
Catheters
Prostatic Stents
Implants
Others

Global Benign Prostatic Hyperplasia Treatment Market Size by End User & CAGR (2025-2032)

Market Overview
Home Healthcare
Hospitals & Clinics
Research & Manufacturing

Global Benign Prostatic Hyperplasia Treatment Market Size & CAGR (2025-2032)

North America (Treatment, Type, Product, End User)
- US
- Canada
Europe (Treatment, Type, Product, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Treatment, Type, Product, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Treatment, Type, Product, End User)
- Brazil
- Rest of Latin America
Middle East & Africa (Treatment, Type, Product, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

Boston Scientific Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott Laboratories (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Astellas Pharma Inc. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teleflex Incorporated (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Olympus Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Coloplast Group (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Asahi Kasei Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Allergan plc (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
IPG Photonics Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Richard Wolf GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biolitec AG (Austria)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Urologix, LLC (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Procept BioRobotics Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lumenis Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
KARL STORZ SE & Co. KG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments

前立腺肥大症治療市場規模、シェア、成長分析：治療法別、タイプ別、製品別、エンドユーザー別、地域別 - 産業予測 2025年～2032年

Benign Prostatic Hyperplasia Treatment Market Size, Share, and Growth Analysis, By Treatment (Minimal Invasive Surgery, Invasive Surgery), By Type (Drug Treatment, Surgical Treatment), By Product, By End User, By Region - Industry Forecast 2025-2032

目次

イントロダクション

調査手法

エグゼクティブサマリー

市場力学と見通し

主な市場の考察

前立腺肥大症治療市場規模：治療法別& CAGR（2025-2032）

前立腺肥大症治療市場規模：タイプ別& CAGR（2025-2032）